Related Experiment Video

Updated: Jun 16, 2026

Spatiotemporal Subcellular Manipulation of the Microtubule Cytoskeleton in the Living Preimplantation Mouse Embryo using Photostatins
08:13

Spatiotemporal Subcellular Manipulation of the Microtubule Cytoskeleton in the Living Preimplantation Mouse Embryo using Photostatins

Published on: November 30, 2021

Tubulin-targeting agents in hybrid drugs

E C Breen1, J J Walsh

  • 1School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland.

Current Medicinal Chemistry
|January 22, 2010
PubMed

Insights

Hybrid drugs combining anti-cancer agents offer a promising approach to overcome drug resistance and improve treatment efficacy. This review explores tubulin-targeting hybrid molecules for enhanced cancer chemotherapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Tubulin-targeting agents are crucial in cancer chemotherapy.
  • Limitations of single agents necessitate combination therapies.
  • Developing hybrid molecules offers potential advantages over traditional combinations.

Purpose of the Study:

  • To review hybrid drugs where at least one component targets tubulin.
  • To evaluate the rationale and potential benefits of such hybrid molecules.
  • To highlight challenges and future directions in hybrid drug development.

Main Methods:

  • Literature review of existing tubulin-targeting hybrid drugs.
  • Analysis of studies investigating activity in multidrug-resistant cancer cell lines.
  • Critical discussion of advantages and disadvantages compared to single agents or combinations.

Main Results:

  • Hybrid drugs may offer enhanced activity beyond equivalent combinations.
  • Investigation focused on overcoming multidrug resistance.
  • Challenges include in vivo metabolism, molecular size, and dosage optimization.

Conclusions:

  • Hybrid drugs targeting tubulin represent a novel strategy in cancer chemotherapy.
  • Potential for improved clinical outcomes and overcoming resistance exists.
  • Further research is needed to address development challenges and optimize therapeutic potential.

More Related Videos

Optimizing Tubulin Yield from Porcine Brain Tissue06:30

Optimizing Tubulin Yield from Porcine Brain Tissue

Published on: October 11, 2024

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.